Department of Surgery »  Faculty »  General Surgery »  Laura J. Esserman, M.D., M.B.A.

Laura J. Esserman, M.D., M.B.A.

Professor of Surgery and Radiology
Division of General Surgery
Chief, Section of Breast Care Surgery
Director, UCSF Carol Franc Buck Breast Care Center

Contact Information

Education

  • 1974-77, Harvard University, A.B.
  • 1978-83, Stanford University, M.D.

Residencies

  • 1983-85, Stanford University School of Medicine, Resident, General Surgery
  • 1988-90, Stanford University School of Medicine, Resident, General Surgery
  • 1990-91, Stanford University School of Medicine, Chief Resident, General Surgery

Fellowships

  • 1985-88, Stanford University School of Medicine, Postdoctoral Fe, Oncology, Medical

Postdoctoral Training

  • 1991-93, Stanford University, M.B.A.

Board Certifications

  • American Board of Surgery - General Surgery - 1992

Program Affiliations

  • UCSF Center of Excellence for Breast Cancer Care
  • UCSF Carol Frank Buck Breast Care Center
  • UCSF Helen Diller Comprehensive Cancer Center

Research Interests

  • Breast Diseases
  • Breast Neoplasms
  • Cancer Vaccines
  • Genes
  • Intraductal Carcinoma
  • Male
  • Mammary
  • Mastectomy
  • Noninfiltrating Carcinoma Lobular
  • Oncogenes
  • Precancerous Conditions
  • Segmental
  • Tumor Suppressor
  • Ultrasonography
  • BRCA1 Protein
  • BRCA2 Protein
  • Infiltrating Duct Carcinoma

Biography

 

Dr. Laura Esserman, M.D., M.B.A is a surgeon and breast cancer oncology specialist practicing at the UCSF Carol Franc Buck Breast Care Center where she has also held the position of Director since 1996.  She co-leads the Breast Oncology Program, the largest of the UCSF Helen Diller Comprehensive Cancer Center's multidisciplinary programs. The program is comprised of 69 faculty members who represent 16 academic specialties and is internationally recognized and well-established with major initiatives in epidemiology, genetics, biology, therapeutics, and clinical cancer care.  She is a professor of Surgery & Radiology at UCSF and Associate Director of the UCSF Helen Diller Family Comprehensive Cancer Center where she has founded and led the program in Translational Informatics. As part of this program, her research has focused on bioinformatics, medical and clinical informatics, systems integration, and clinical care delivery.

 

Dr. Esserman received her Bachelor's degree in History of Science from Harvard University and completed her M.D. at Stanford University. She completed her surgery residency and oncology fellowship at Stanford University Medical Center.  After her training, she joined the faculty at Stanford and received a Hartford fellowship to attend Stanford Business School where she received her M.B.A. in 1993.  She then joined the faculty at the University of California, San Francisco.  She has worked at UCSF to develop interdisciplinary teams of clinicians and researchers to bring the best care to patients and find the best platform to integrate translational research and improve the delivery of breast cancer care.

 

Dr. Esserman has been a leader in the I-SPY TRIAL collaboration, a National Cancer Institute's (NCI) Center for Bioinformatics and SPORE program. In 2005, she received the NCI SPORE Investigator of the Year Award, an internationally recognized honor and designation.  As the Primary Investigator of a Department of Defense-funded Center of Excellence grant, she has also brought together an extraordinary, multidisciplinary group of investigators and health care industry partners to work on critical problems concerning the quality of breast cancer care. Highly respected by her peers, Dr. Esserman was named to the list of U.S. News "America's Top Doctors," a distinction reserved for the top 1% of physicians in the nation for a given specialty.

 

Dr. Esserman is a prolific writer with numerous publications in peer-reviewed journals covering all aspects of breast health including information systems, immunology, decision making, health policy and the use of imaging. She speaks extensively at public and private forums within the U.S. and internationally.  Overall, Dr. Esserman's research and writing tends to focus on the goal of giving patients better access to accurate information so that they can become partners in their health care.

 

Publications

Most recent publications from a total of 203
  1. Eklund M, O'Donoghue C, Esserman LJ. Aggregate cost of mammography screening in the United States. Ann Intern Med. 2014 Aug 19; 161(4):305. View in PubMed
  2. Eklund M, O'Donoghue C, Esserman LJ. Aggregate cost of mammography screening in the United States. Ann Intern Med. 2014 Aug 19; 161(4):305. View in PubMed
  3. Peled AW, Foster RD, Ligh C, Esserman LJ, Fowble B, Sbitany H. Impact of Total Skin-Sparing Mastectomy Incision Type on Reconstructive Complications following Radiation Therapy. Plast Reconstr Surg. 2014 Aug; 134(2):169-75. View in PubMed
  4. Esserman L, Hayes M, Alvarado M. Haste makes waste, but lack of urgency is opportunity lost. Breast Cancer Res Treat. 2014 Aug; 147(1):223-4. View in PubMed
  5. Esserman L, O'Kane ME. Moving beyond the breast cancer screening debate. J Womens Health (Larchmt). 2014 Aug; 23(8):629-30. View in PubMed
  6. Peled AW, Sbitany H, Foster RD, Esserman LJ. Oncoplastic mammoplasty as a strategy for reducing reconstructive complications associated with postmastectomy radiation therapy. Breast J. 2014 May; 20(3):302-7. View in PubMed
  7. Peled AW, Duralde E, Foster RD, Fiscalini AS, Esserman LJ, Hwang ES, Sbitany H. Patient-reported outcomes and satisfaction after total skin-sparing mastectomy and immediate expander-implant reconstruction. Ann Plast Surg. 2014 May; 72 Suppl 1:S76-80. View in PubMed
  8. Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014 May; 15(6):e234-42. View in PubMed
  9. Cureton EL, Yau C, Alvarado MD, Krontiras H, Ollila DW, Ewing CA, Monnier S, Esserman LJ. Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2014 Sep; 21(9):2889-96. View in PubMed
  10. Esserman LJ, DeMichele A. Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change? Clin Cancer Res. 2014 Jul 15; 20(14):3632-6. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Laura J. Esserman, M.D., M.B.A.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X